ArticleNeuro-oncology advances

Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts.

Rachael A Vaubel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.